Advancing Equitable Access to Care for Everyone

Advancing Access and Innovation for Health Equity

or more than a decade, Johnson & Johnson has been recognized by the independent Access to Medicine Foundation as one of the top three companies working to advance access to medicines and technologies in low- and middle-income countries.

This consistent recognition of our leadership is the result of a longstanding, deliberate and focused strategy aimed at solving some of the most difficult global health challenges and advancing equitable access to care for everyone, everywhere.

Learn more about how we never stop working to ensure good health for the people we serve.

More Than a Decade of Leadership in Access to Innovation

Our relentless focus on equitable access to healthcare is reflected in its consistent high ranking on the Access to Medicine Index (ATMI), a biennial report card that grades the world’s largest pharmaceutical companies on their efforts to distribute medications, vaccines and diagnostics to low- and middle-income countries. For ten years, Johnson & Johnson has placed in the top three on the list and in the 2021 report, we have once again earned a #3 spot overall, and advanced two places in the research and development category to take the #2 spot. Our consistent performance in the top three position underscores the our deep history of ensuring people in underserved communities receive the treatments they need.

expand

Our Commitment to Advance Access to Medicines and Technologies

4 Ways Johnson & Johnson Has Worked to Make Access to Medicines Around the World More Equitable

The Access to Medicine Index, a ranking of pharmaceutical companies' work to distribute medications to low- and middle-income countries, just named Johnson & Johnson #3 on its biennial list, underscoring the company's deep history of ensuring people in underserved communities receive the treatments they need.

ON NOW

2021 Access to Medicine Index Ranks Johnson & Johnson to Top 3 Companies Advancing Access to Medicines

Everyone deserves to live a healthy life. Yet all too often disease or inequities in access to care compromise a person’s health.

ON NOW

2021 ATMI Report Card

ON NOW

ATMI Best Practice: DREAMS Thina Abantu Abasha

ON NOW

ATMI Best Practice: Broadening access to tuberculosis and HIV medicines

ON NOW

2020 Janssen Transparency Report

ON NOW

Spotlight on Our Breakthrough Access Programs

Champions for Access

We are committed, more than ever before, to advance a safer, healthier and more equitable world where everyone can thrive.

— Paul Stoffels, M.D., Vice Chairman of the Executive Committee, Chief Scientific Officer, Johnson & Johnson

Our Global Public Health unit works to expand equitable access to our medicines and technologies for the world's most underserved people.

— Martin Fitchet, M.D., Global Head, Global Public Health

Our research and development pipeline focuses heavily on diseases that primarily impact underserved populations—and we integrate access planning into everything we do.

— Rusandra Draghia-Akli, M.D., Ph.D., Global Head, Global Public Health R&D

Our 25 years of experience in addressing global health challenges is informing our response to COVID-19, a global crisis that is laying bare the global inequities in accessing care.

— Adrian Thomas, M.D., Vice President, Strategy & External Affairs, Global Public Health

We're committed to expanding equitable access to care in Africa by strengthening health systems, supporting frontline health workers and investing in local partnerships.

— Stacy Meyer, Vice President, Africa Implementation & Impact, Global Public Health

Internet Explorer is no longer supported by this website.

Advancing Equitable Access to Care for Everyone, Everywhere

More Than a Decade of Leadership in Access to Innovation

Our Commitment to Advance Access to Medicines and Technologies

Spotlight on Our Breakthrough Access Programs

Champions for Access